Technology | July 01, 2015

American College of Cardiology Develops Statin Intolerance App

App to guide clinicians in treating patients with muscle pain during statin therapy

ACC, Statin Intolerance App, statin therapy, muscle symptoms, pain

July 1, 2015 - The American College of Cardiology (ACC) Statin Intolerance App is now available to help guide clinicians through the process of managing and treating patients who report muscle symptoms while on statin therapy.

Although muscle symptoms may occur while on statin therapy, true statin intolerance is uncommon. Because of the abundance of research showing the benefits of statin therapy for heart disease risk reduction, clinicians should partner with patients in determining if the patient is truly statin-intolerant. Patients reporting muscle symptoms while on a statin with should be managed and treated with cycles of discontinuation and rechallenge to identify a tolerated statin and dose.

The ACC Statin Intolerance App is designed to help guide this process. Using the app, clinicians can answer questions to evaluate possible intolerance to a patient's current statin prescription, follow steps to manage and treat a patient who reports muscle symptoms on a statin, and compare statin characteristics and drug interactions to inform management of LDL, or "bad" cholesterol, related risks. The app may also be helpful as a resource and teaching tool for students, trainees and clinicians less familiar with standard guidance and protocols for addressing statin intolerance.

The app was developed as part of the ACC's LDL: Address the Risk Initiative, a quality program designed to improve patient outcomes by increasing awareness of the gaps in managing cholesterol, including the importance of managing the risks of high LDL. The app is also part of a larger and ongoing effort by the college to help its members and other clinicians translate guidelines and other clinical policy statements into practice at the point of care. Content in the app was derived from the ACC/AHA's (American Heart Association) 2013 Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults as well as prescribing information from each statin.

Financial support for the LDL: Address the Risk Initiative was provided by Amgen Inc. All of the content was independently developed with no sponsor involvement.

The ACC Statin Intolerance App is available for free, in both Web and mobile versions, on the ACC website or in the iTunes or Google Play app stores.

For more information: www.acc.org

Related Content

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after biologic therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

Coronary CT angiography images of a coronary artery depicting the perivascular fat attenuation index (FAI) before and after psoriasis biologic drug therapy at one-year follow-up. Patients had excellent response to biologic therapy, showing clear reductions in the inflammation in plaques that cause heart attacks and stokes. Image from the Oxford Academic Cardiovascular CT Core Lab and Lab of Inflammation and Cardiometabolic Diseases at NHLBI.

 

Feature | Pharmaceuticals | July 31, 2019
July 31, 2019 — Researchers found anti-inflammatory drug therapies used to treat moderate to severe psoriasis can sig
Quantum Genomics Enrolls First Patient in QUORUM Phase IIb Study of Firibastat
News | Pharmaceuticals | June 14, 2019
Quantum Genomics announced the enrollment of the first patient in its QUORUM Phase IIb study of its lead clinical...
FDA Grants Priority Review for Vascepa sNDA
News | Pharmaceuticals | May 29, 2019
Amarin Corp. plc announced that its supplemental new drug application (sNDA) for Vascepa (icosapent ethyl) capsules has...
Vascepa Markedly Reduces First, Repeat and Total Cardiovascular Events
News | Pharmaceuticals | March 29, 2019
Taking a high dose of icosapent ethyl significantly reduces the occurrence of first, subsequent and total ischemic...
Bempedoic Acid Combination Tablet Significantly Lowers LDL-Cholesterol

Image courtesy of Esperion

News | Pharmaceuticals | March 25, 2019
Phase 3 results from Study 2, also known as CLEAR WISDOM, of bempedoic acid were recently presented at the American...
Aurobindo Pharma Adds to Nationwide Valsartan Blood Pressure Medication Recall
News | Pharmaceuticals | January 10, 2019
January 10, 2019 — Aurobindo Pharma USA Inc.
Mylan Expands Nationwide Recall of Valsartan Blood Pressure Medication
News | Pharmaceuticals | December 11, 2018
December 11, 2018 — Mylan Pharmaceuticals is expanding its consumer-level voluntary nationwide recall to include all
Farxiga Reduces Heart Failure Hospitalization, Cardiovascular Death for Type 2 Diabetes
News | Pharmaceuticals | November 15, 2018
AstraZeneca announced positive full results from the DECLARE-TIMI 58 cardiovascular (CV) outcomes trial (CVOT) for...
Vascepa and Statins Significantly Reduce Cardiovascular Events in the REDUCE-IT trial. #AHA #AHA18 #AHA2018
News | Pharmaceuticals | November 13, 2018
A study in the current edition of the New England Journal of Medicine shows that a particular treatment significantly...
Overlay Init